Inhibikase Therapeutics, Inc. Shares Outstanding (Cover Page)
Inhibikase Therapeutics, Inc. (IKT) had Shares Outstanding (Cover Page) of 139.54 million shares as of 2026-08-04, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Cover Page
dei:EntityCommonStockSharesOutstanding · last filed 2026-08-11
- 2026-08-04: Entity Common Stock, Shares Outstanding 139.54M shares.
- 2026-05-01: Entity Common Stock, Shares Outstanding 132.03M shares.
- 2026-03-20: Entity Common Stock, Shares Outstanding 132.03M shares.
- 2025-11-07: Entity Common Stock, Shares Outstanding 75.18M shares.
| Period end | Entity Common Stock, Shares Outstanding |
|---|---|
| 2026-08-04 | 139.54M shares 10-Q · filed 2026-08-11 |
| 2026-05-01 | 132.03M shares 10-Q · filed 2026-05-12 |
| 2026-03-20 | 132.03M shares 10-K · filed 2026-03-26 |
| 2025-11-07 | 75.18M shares 10-Q · filed 2025-11-14 |
| 2025-08-07 | 74.52M shares 10-Q · filed 2025-08-14 |
| 2025-05-01 | 74.34M shares 10-Q · filed 2025-05-14 |
| 2025-04-15 | 74.34M shares 10-K/A · filed 2025-04-25 |
| 2025-03-20 | 74.34M shares 10-K · filed 2025-03-27 |
| 2024-11-01 | 67.19M shares 10-Q · filed 2024-11-14 |
| 2024-08-01 | 7.46M shares 10-Q · filed 2024-08-14 |
| 2024-05-01 | 6.48M shares 10-Q · filed 2024-05-15 |
| 2024-03-15 | 6.48M shares 10-K · filed 2024-03-27 |
| 2023-11-01 | 6.17M shares 10-Q · filed 2023-11-14 |
| 2023-08-01 | 5.35M shares 10-Q · filed 2023-08-14 |
| 2023-05-01 | 31.06M shares 10-Q · filed 2023-05-15 |
| 2023-03-14 | 28.98M shares 10-K/A · filed 2023-10-16 |
| 2022-11-01 | 25.23M shares 10-Q · filed 2022-11-14 |
| 2022-08-01 | 25.23M shares 10-Q · filed 2022-08-12 |
| 2022-05-02 | 25.23M shares 10-Q · filed 2022-05-16 |
| 2022-03-14 | 25.23M shares 10-K · filed 2022-03-31 |
| 2021-11-10 | 25.16M shares 10-Q · filed 2021-11-15 |
| 2021-07-31 | 25.13M shares 10-Q · filed 2021-08-16 |
| 2021-04-30 | 10.06M shares 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |